Title:CRISPR/Cas9 Tool for MicroRNAs Editing in Cardiac Development,
Function, and Disease
Volume: 12
Issue: 1
Author(s): Leila Abkhooie and Shirin Saberianpour*
Affiliation:
- Vascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Keywords:
CRISPR/Cas9, MicroRNAs, cardiac development, gene editing techniques, cytoplasm, organ evolution.
Abstract: CRISPR/Cas9 is a powerful gene-editing technology. Extensive scientific data exist that
the CRISPR/Cas9 system can target small, non-coding, active RNA molecules, including microRNAs
(miRNAs). miRNAs have been recognized as key regulators of different cell biological
processes, such as the modulation of fibrosis and cardiac hypertrophy, as well as the regulation of
cardiomyocytes. Also, it has been demonstrated that miRNAs strongly affect organ evolution, and
that the concentration of miRNAs can involve the differentiation, development, and function of different
organs. In addition, the current findings clearly indicate that miRNAs can select and control
their targets based on their concentrations. CRISPR/Cas9 genome-editing technology is a stronger
system for stopping miRNAs than previous methods, including antisense inhibitors. CRISPR/Cas9
tools can be used to eliminate small areas of DNA and determine miRNA in cases where similar
groups of miRNAs are in the same strand. Herein, besides other emerging strategies, we critically
summarize the recent investigations linking miRNA-targeted therapeutics and CRISPR/Cas9 system
to clarify and combine different delivery platforms and cell-fate engineering of miRNAs function
and miRNA-based therapeutic intervention in cardiac development, function, and disease. Based on
our findings from the literature, it appears that the use of the CRISPR/Cas technology provides new
perspectives for understanding the molecular mechanism of cardiovascular disease and can be effective
in treating and controlling cardiac development, function, and disease in the future.
